Company: NCEL
Filing Date: 2025-03-31
Form Type: F-4/A
Source: 0001213900-25-026428
Chunk: 810

Company: NewcelX Ltd.
Filing Date: 2025-03-31
Form: F-4/A
Chunk 810
---
0.02) per pre -fundedwarrant. The Company engaged Laidlaw & Company (UK) Ltd. (“Laidlaw”) to serve as the placement agent for the Company in connection with the above -describedoffering. The Company agreed to pay Laidlaw a cash placement fee of $ 700,000and warrants to purchase common shares equal to 5% of the common shares sold in the offering. In addition, the Company and BVF agreed that until the 30 thday following receipt of the official written minutes from the end of the Phase 2 meeting to be held by the Company with the FDA (the “Election Deadline”), among other closing conditions, BVF shall have the right to purchase at a second closing up to $ 20million in units, with each unit consisting of one common share and/or pre -fundedwarrants to purchase one common share, as well as receive warrants to purchase up to 150% of the number of common shares and/or pre -fundedwarrant shares purchased in the second closing, at a purchase price of $ 1.50per unit. The warrants will have a term of five years, will have an exercise price of $ 2.03per share and will be exercisable for pre -fundedwarrants if, at their expiration, BVF will be unable to purchase common shares due to its beneficial ownership limitation. Pursuant to the purchase agreement, the Company agreed to grant BVF the right to participate in future offerings of the Company’s securities for a period from the first closing (the “First Closing”) until the earlier of (i) the 30 -monthanniversary of the initial closing date or (ii) until such time that BVF retains beneficial ownership of less than 9.9% of the issued and outstanding Common Shares. on the same terms, conditions and price provided for in the subsequent financing or the right to purchase a comparable security with a beneficial ownership limitation. In addition, the Annex F-135 NLS PHARMACEUTICS LTD.
NOTES TO THE FINANCIAL STATEMENTS

Company agreed to grant BVF the right to nominate one member to the Company’s Board of Directors and shall continue to recommend to its shareholders to elect such member for a period from the First Closing until such time that BVF retains beneficial ownership of less than 9.9% of the issued and outstanding common shares. On October 7, 2022, the Company closed on a securities purchase agreement for the issuance